PCRX (pacira.com) יחס שווי שוק לשווי בספרים
The price indicator on the Pacira BioSciences (PCRX) chart reflects the dynamics of a business that relies on its own sterile manufacturing facilities in the UK and US to produce analgesics. However, generic pressure on the drug Exparel threatens future revenues, which currently stand at 2.17. Simultaneously, Pacira BioSciences (PCRX) is implementing eco-friendly packaging and optimizing plant energy costs as part of its ESG strategy.
%3A%20%D7%A9%D7%95%D7%95%D7%99%20%D7%A9%D7%95%D7%A7%20%D7%91%D7%99%D7%97%D7%A1%20%D7%9C%D7%A0%D7%9B%D7%A1%D7%99%D7%9D%20%D7%A0%D7%A7%D7%99%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_PCRX_-_Pacira-BioSciences_-_Market-Capitalization-to-Net-Assets "PCRX יחס שווי שוק לערך בספרים Pacira Corp (04.07.2022 - 27.10.2026) | 👁️GURU.Markets👁️")
פילוחי מדדים פיננסיים ומדדי שוק עבור Pacira Pharmaceuticals (PCRX)
This indicator determines the market revaluation of net assets by comparing the stock price to the company's actual capital to filter out volatile noise. Analyzing the market capitalization-to-book value ratio allows for an assessment of the stability of Pacira BioSciences (PCRX), where the asset premium is justified by the unique patent protection of Exparel and leadership in the non-opioid pain management segment.